nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—CYP2B6—Thiotepa—urinary bladder cancer	0.138	0.208	CbGbCtD
Enzalutamide—ABCB1—Mitomycin—urinary bladder cancer	0.0933	0.141	CbGbCtD
Enzalutamide—ALB—Fluorouracil—urinary bladder cancer	0.0439	0.0662	CbGbCtD
Enzalutamide—CYP3A4—Thiotepa—urinary bladder cancer	0.0424	0.0638	CbGbCtD
Enzalutamide—CYP2B6—Cisplatin—urinary bladder cancer	0.0381	0.0573	CbGbCtD
Enzalutamide—CYP2C8—Fluorouracil—urinary bladder cancer	0.0339	0.0511	CbGbCtD
Enzalutamide—CYP3A5—Etoposide—urinary bladder cancer	0.0295	0.0444	CbGbCtD
Enzalutamide—CYP2C8—Etoposide—urinary bladder cancer	0.0283	0.0427	CbGbCtD
Enzalutamide—ABCB1—Gemcitabine—urinary bladder cancer	0.0269	0.0405	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—urinary bladder cancer	0.0255	0.0384	CbGbCtD
Enzalutamide—ALB—Methotrexate—urinary bladder cancer	0.0242	0.0365	CbGbCtD
Enzalutamide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0237	0.0357	CbGbCtD
Enzalutamide—AR—scrotum—urinary bladder cancer	0.0204	0.258	CbGeAlD
Enzalutamide—CYP2C9—Cisplatin—urinary bladder cancer	0.0201	0.0303	CbGbCtD
Enzalutamide—ABCB1—Cisplatin—urinary bladder cancer	0.0195	0.0294	CbGbCtD
Enzalutamide—ABCB1—Etoposide—urinary bladder cancer	0.0192	0.0289	CbGbCtD
Enzalutamide—ABCB1—Doxorubicin—urinary bladder cancer	0.0131	0.0197	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—urinary bladder cancer	0.0127	0.0191	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.0123	0.0186	CbGbCtD
Enzalutamide—CYP3A4—Etoposide—urinary bladder cancer	0.0115	0.0173	CbGbCtD
Enzalutamide—Nilutamide—POR—urinary bladder cancer	0.01	1	CrCbGaD
Enzalutamide—AR—penis—urinary bladder cancer	0.00921	0.117	CbGeAlD
Enzalutamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00784	0.0118	CbGbCtD
Enzalutamide—CYP2C19—urine—urinary bladder cancer	0.00567	0.0719	CbGeAlD
Enzalutamide—CYP2C9—urine—urinary bladder cancer	0.0044	0.0557	CbGeAlD
Enzalutamide—CYP3A4—urine—urinary bladder cancer	0.00335	0.0425	CbGeAlD
Enzalutamide—CYP2D6—urine—urinary bladder cancer	0.0033	0.0418	CbGeAlD
Enzalutamide—AR—prostate gland—urinary bladder cancer	0.0022	0.0279	CbGeAlD
Enzalutamide—AR—seminal vesicle—urinary bladder cancer	0.00186	0.0236	CbGeAlD
Enzalutamide—AR—epithelium—urinary bladder cancer	0.00162	0.0205	CbGeAlD
Enzalutamide—CYP3A5—prostate gland—urinary bladder cancer	0.0016	0.0203	CbGeAlD
Enzalutamide—AR—smooth muscle tissue—urinary bladder cancer	0.00156	0.0197	CbGeAlD
Enzalutamide—AR—renal system—urinary bladder cancer	0.0015	0.019	CbGeAlD
Enzalutamide—AR—urethra—urinary bladder cancer	0.00147	0.0186	CbGeAlD
Enzalutamide—CYP2C8—renal system—urinary bladder cancer	0.00121	0.0154	CbGeAlD
Enzalutamide—AR—female reproductive system—urinary bladder cancer	0.0012	0.0152	CbGeAlD
Enzalutamide—CYP3A5—renal system—urinary bladder cancer	0.00109	0.0139	CbGeAlD
Enzalutamide—CYP2B6—renal system—urinary bladder cancer	0.00109	0.0138	CbGeAlD
Enzalutamide—AR—vagina—urinary bladder cancer	0.00109	0.0137	CbGeAlD
Enzalutamide—CYP2C19—vagina—urinary bladder cancer	0.00101	0.0127	CbGeAlD
Enzalutamide—CYP2C8—female reproductive system—urinary bladder cancer	0.000971	0.0123	CbGeAlD
Enzalutamide—CYP2C8—vagina—urinary bladder cancer	0.000878	0.0111	CbGeAlD
Enzalutamide—CYP2B6—female reproductive system—urinary bladder cancer	0.000871	0.011	CbGeAlD
Enzalutamide—CYP2C9—female reproductive system—urinary bladder cancer	0.000862	0.0109	CbGeAlD
Enzalutamide—ABCB1—prostate gland—urinary bladder cancer	0.000853	0.0108	CbGeAlD
Enzalutamide—CYP3A4—renal system—urinary bladder cancer	0.000821	0.0104	CbGeAlD
Enzalutamide—ALB—lymph node—urinary bladder cancer	0.000808	0.0102	CbGeAlD
Enzalutamide—CYP2D6—renal system—urinary bladder cancer	0.000808	0.0102	CbGeAlD
Enzalutamide—CYP3A5—vagina—urinary bladder cancer	0.000792	0.01	CbGeAlD
Enzalutamide—CYP2B6—vagina—urinary bladder cancer	0.000787	0.00997	CbGeAlD
Enzalutamide—ABCB1—seminal vesicle—urinary bladder cancer	0.000721	0.00913	CbGeAlD
Enzalutamide—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.000712	0.00522	CcSEcCtD
Enzalutamide—AR—lymph node—urinary bladder cancer	0.000702	0.00889	CbGeAlD
Enzalutamide—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000694	0.00509	CcSEcCtD
Enzalutamide—Neutropenia—Gemcitabine—urinary bladder cancer	0.000691	0.00507	CcSEcCtD
Enzalutamide—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.000691	0.00507	CcSEcCtD
Enzalutamide—Urethral disorder—Thiotepa—urinary bladder cancer	0.000689	0.00505	CcSEcCtD
Enzalutamide—Diarrhoea—Mitomycin—urinary bladder cancer	0.000679	0.00498	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000675	0.00495	CcSEcCtD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—urinary bladder cancer	0.000671	0.00492	CcSEcCtD
Enzalutamide—Pneumonia—Gemcitabine—urinary bladder cancer	0.000663	0.00486	CcSEcCtD
Enzalutamide—CYP3A4—female reproductive system—urinary bladder cancer	0.000657	0.00833	CbGeAlD
Enzalutamide—Dizziness—Mitomycin—urinary bladder cancer	0.000657	0.00482	CcSEcCtD
Enzalutamide—Pneumonia—Fluorouracil—urinary bladder cancer	0.000651	0.00478	CcSEcCtD
Enzalutamide—Infestation—Fluorouracil—urinary bladder cancer	0.000648	0.00475	CcSEcCtD
Enzalutamide—Infestation NOS—Fluorouracil—urinary bladder cancer	0.000648	0.00475	CcSEcCtD
Enzalutamide—CYP2D6—female reproductive system—urinary bladder cancer	0.000647	0.00819	CbGeAlD
Enzalutamide—Angiopathy—Thiotepa—urinary bladder cancer	0.000638	0.00468	CcSEcCtD
Enzalutamide—Haematuria—Gemcitabine—urinary bladder cancer	0.000628	0.00461	CcSEcCtD
Enzalutamide—ABCB1—epithelium—urinary bladder cancer	0.000626	0.00793	CbGeAlD
Enzalutamide—Headache—Mitomycin—urinary bladder cancer	0.000622	0.00456	CcSEcCtD
Enzalutamide—Mental disorder—Thiotepa—urinary bladder cancer	0.000616	0.00452	CcSEcCtD
Enzalutamide—Epistaxis—Fluorouracil—urinary bladder cancer	0.000611	0.00448	CcSEcCtD
Enzalutamide—Sinusitis—Fluorouracil—urinary bladder cancer	0.000608	0.00446	CcSEcCtD
Enzalutamide—Rhinitis—Gemcitabine—urinary bladder cancer	0.000593	0.00435	CcSEcCtD
Enzalutamide—Back pain—Thiotepa—urinary bladder cancer	0.000592	0.00434	CcSEcCtD
Enzalutamide—Neutropenia—Etoposide—urinary bladder cancer	0.00059	0.00433	CcSEcCtD
Enzalutamide—Pharyngitis—Gemcitabine—urinary bladder cancer	0.000587	0.0043	CcSEcCtD
Enzalutamide—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000584	0.00428	CcSEcCtD
Enzalutamide—Rhinitis—Fluorouracil—urinary bladder cancer	0.000583	0.00427	CcSEcCtD
Enzalutamide—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000582	0.00427	CcSEcCtD
Enzalutamide—ABCB1—renal system—urinary bladder cancer	0.000581	0.00736	CbGeAlD
Enzalutamide—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000581	0.00426	CcSEcCtD
Enzalutamide—Urethral disorder—Gemcitabine—urinary bladder cancer	0.00058	0.00425	CcSEcCtD
Enzalutamide—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.000578	0.00424	CcSEcCtD
Enzalutamide—Pharyngitis—Fluorouracil—urinary bladder cancer	0.000577	0.00423	CcSEcCtD
Enzalutamide—ABCB1—urethra—urinary bladder cancer	0.000571	0.00723	CbGeAlD
Enzalutamide—Musculoskeletal pain—Epirubicin—urinary bladder cancer	0.00057	0.00418	CcSEcCtD
Enzalutamide—Pneumonia—Etoposide—urinary bladder cancer	0.000566	0.00415	CcSEcCtD
Enzalutamide—Infestation—Etoposide—urinary bladder cancer	0.000562	0.00412	CcSEcCtD
Enzalutamide—Infestation NOS—Etoposide—urinary bladder cancer	0.000562	0.00412	CcSEcCtD
Enzalutamide—Leukopenia—Thiotepa—urinary bladder cancer	0.000548	0.00402	CcSEcCtD
Enzalutamide—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000544	0.00399	CcSEcCtD
Enzalutamide—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000542	0.00397	CcSEcCtD
Enzalutamide—Urethral disorder—Cisplatin—urinary bladder cancer	0.00054	0.00396	CcSEcCtD
Enzalutamide—Angiopathy—Gemcitabine—urinary bladder cancer	0.000536	0.00393	CcSEcCtD
Enzalutamide—Convulsion—Thiotepa—urinary bladder cancer	0.00053	0.00389	CcSEcCtD
Enzalutamide—Hypertension—Thiotepa—urinary bladder cancer	0.000528	0.00387	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.000528	0.00387	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—urinary bladder cancer	0.000523	0.00383	CcSEcCtD
Enzalutamide—Arthralgia—Thiotepa—urinary bladder cancer	0.000521	0.00382	CcSEcCtD
Enzalutamide—Anxiety—Thiotepa—urinary bladder cancer	0.000519	0.00381	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000517	0.00379	CcSEcCtD
Enzalutamide—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000502	0.00368	CcSEcCtD
Enzalutamide—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000499	0.00366	CcSEcCtD
Enzalutamide—Back pain—Gemcitabine—urinary bladder cancer	0.000498	0.00365	CcSEcCtD
Enzalutamide—Infection—Thiotepa—urinary bladder cancer	0.000496	0.00364	CcSEcCtD
Enzalutamide—Urethral disorder—Etoposide—urinary bladder cancer	0.000495	0.00363	CcSEcCtD
Enzalutamide—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00049	0.00359	CcSEcCtD
Enzalutamide—Sepsis—Epirubicin—urinary bladder cancer	0.000489	0.00359	CcSEcCtD
Enzalutamide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000489	0.00359	CcSEcCtD
Enzalutamide—Skin disorder—Thiotepa—urinary bladder cancer	0.000485	0.00356	CcSEcCtD
Enzalutamide—ABCB1—female reproductive system—urinary bladder cancer	0.000465	0.00589	CbGeAlD
Enzalutamide—Leukopenia—Gemcitabine—urinary bladder cancer	0.000461	0.00338	CcSEcCtD
Enzalutamide—Angiopathy—Etoposide—urinary bladder cancer	0.000458	0.00336	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000455	0.00334	CcSEcCtD
Enzalutamide—Leukopenia—Fluorouracil—urinary bladder cancer	0.000453	0.00332	CcSEcCtD
Enzalutamide—Sepsis—Doxorubicin—urinary bladder cancer	0.000453	0.00332	CcSEcCtD
Enzalutamide—Paraesthesia—Thiotepa—urinary bladder cancer	0.000448	0.00329	CcSEcCtD
Enzalutamide—Hypertension—Gemcitabine—urinary bladder cancer	0.000444	0.00326	CcSEcCtD
Enzalutamide—Convulsion—Fluorouracil—urinary bladder cancer	0.000438	0.00322	CcSEcCtD
Enzalutamide—Arthralgia—Gemcitabine—urinary bladder cancer	0.000438	0.00321	CcSEcCtD
Enzalutamide—Hot flush—Epirubicin—urinary bladder cancer	0.000437	0.00321	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000435	0.00319	CcSEcCtD
Enzalutamide—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000434	0.00318	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000431	0.00316	CcSEcCtD
Enzalutamide—Fatigue—Thiotepa—urinary bladder cancer	0.000431	0.00316	CcSEcCtD
Enzalutamide—Leukopenia—Cisplatin—urinary bladder cancer	0.000429	0.00315	CcSEcCtD
Enzalutamide—Back pain—Etoposide—urinary bladder cancer	0.000425	0.00312	CcSEcCtD
Enzalutamide—ABCB1—vagina—urinary bladder cancer	0.000421	0.00533	CbGeAlD
Enzalutamide—Infection—Gemcitabine—urinary bladder cancer	0.000417	0.00306	CcSEcCtD
Enzalutamide—Convulsion—Cisplatin—urinary bladder cancer	0.000416	0.00305	CcSEcCtD
Enzalutamide—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000412	0.00302	CcSEcCtD
Enzalutamide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000411	0.00302	CcSEcCtD
Enzalutamide—Infection—Fluorouracil—urinary bladder cancer	0.00041	0.00301	CcSEcCtD
Enzalutamide—Skin disorder—Gemcitabine—urinary bladder cancer	0.000408	0.00299	CcSEcCtD
Enzalutamide—Anxiety—Cisplatin—urinary bladder cancer	0.000407	0.00299	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000406	0.00297	CcSEcCtD
Enzalutamide—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000405	0.00297	CcSEcCtD
Enzalutamide—Hot flush—Doxorubicin—urinary bladder cancer	0.000405	0.00297	CcSEcCtD
Enzalutamide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000404	0.00297	CcSEcCtD
Enzalutamide—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.000401	0.00294	CcSEcCtD
Enzalutamide—Vertigo—Etoposide—urinary bladder cancer	0.000395	0.0029	CcSEcCtD
Enzalutamide—Leukopenia—Etoposide—urinary bladder cancer	0.000393	0.00289	CcSEcCtD
Enzalutamide—Infection—Cisplatin—urinary bladder cancer	0.000389	0.00285	CcSEcCtD
Enzalutamide—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000384	0.00282	CcSEcCtD
Enzalutamide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000383	0.00281	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000383	0.00281	CcSEcCtD
Enzalutamide—Convulsion—Etoposide—urinary bladder cancer	0.000381	0.00279	CcSEcCtD
Enzalutamide—Skin disorder—Cisplatin—urinary bladder cancer	0.00038	0.00279	CcSEcCtD
Enzalutamide—Insomnia—Gemcitabine—urinary bladder cancer	0.00038	0.00279	CcSEcCtD
Enzalutamide—Hypertension—Etoposide—urinary bladder cancer	0.000379	0.00278	CcSEcCtD
Enzalutamide—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000377	0.00277	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000376	0.00276	CcSEcCtD
Enzalutamide—Dry skin—Epirubicin—urinary bladder cancer	0.000375	0.00275	CcSEcCtD
Enzalutamide—Insomnia—Fluorouracil—urinary bladder cancer	0.000374	0.00274	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000372	0.00273	CcSEcCtD
Enzalutamide—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000371	0.00272	CcSEcCtD
Enzalutamide—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000366	0.00268	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000363	0.00266	CcSEcCtD
Enzalutamide—Fatigue—Gemcitabine—urinary bladder cancer	0.000362	0.00266	CcSEcCtD
Enzalutamide—Muscular weakness—Epirubicin—urinary bladder cancer	0.000361	0.00265	CcSEcCtD
Enzalutamide—Asthenia—Thiotepa—urinary bladder cancer	0.000358	0.00263	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000357	0.00262	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000357	0.00262	CcSEcCtD
Enzalutamide—Infection—Etoposide—urinary bladder cancer	0.000356	0.00261	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—urinary bladder cancer	0.000353	0.00259	CcSEcCtD
Enzalutamide—Pruritus—Thiotepa—urinary bladder cancer	0.000353	0.00259	CcSEcCtD
Enzalutamide—Paraesthesia—Cisplatin—urinary bladder cancer	0.000352	0.00258	CcSEcCtD
Enzalutamide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000351	0.00258	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000351	0.00258	CcSEcCtD
Enzalutamide—Skin disorder—Etoposide—urinary bladder cancer	0.000348	0.00256	CcSEcCtD
Enzalutamide—Dry skin—Doxorubicin—urinary bladder cancer	0.000347	0.00254	CcSEcCtD
Enzalutamide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000342	0.00251	CcSEcCtD
Enzalutamide—Bronchitis—Epirubicin—urinary bladder cancer	0.00034	0.00249	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—urinary bladder cancer	0.000339	0.00249	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000339	0.00248	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000338	0.00248	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—urinary bladder cancer	0.000337	0.00247	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—urinary bladder cancer	0.000337	0.00247	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000334	0.00245	CcSEcCtD
Enzalutamide—Neutropenia—Epirubicin—urinary bladder cancer	0.000331	0.00242	CcSEcCtD
Enzalutamide—Dizziness—Thiotepa—urinary bladder cancer	0.00033	0.00242	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000329	0.00241	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—urinary bladder cancer	0.000327	0.0024	CcSEcCtD
Enzalutamide—Paraesthesia—Etoposide—urinary bladder cancer	0.000322	0.00236	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—urinary bladder cancer	0.000321	0.00236	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—urinary bladder cancer	0.000318	0.00233	CcSEcCtD
Enzalutamide—Pneumonia—Epirubicin—urinary bladder cancer	0.000317	0.00233	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—urinary bladder cancer	0.000315	0.00231	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—urinary bladder cancer	0.000315	0.00231	CcSEcCtD
Enzalutamide—Bronchitis—Doxorubicin—urinary bladder cancer	0.000315	0.00231	CcSEcCtD
Enzalutamide—Headache—Thiotepa—urinary bladder cancer	0.000313	0.00229	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00031	0.00227	CcSEcCtD
Enzalutamide—Fatigue—Etoposide—urinary bladder cancer	0.000309	0.00227	CcSEcCtD
Enzalutamide—Neutropenia—Doxorubicin—urinary bladder cancer	0.000306	0.00224	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000304	0.00223	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000302	0.00222	CcSEcCtD
Enzalutamide—Asthenia—Gemcitabine—urinary bladder cancer	0.000301	0.00221	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—urinary bladder cancer	0.000301	0.0022	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—urinary bladder cancer	0.0003	0.0022	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000299	0.00219	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—urinary bladder cancer	0.000297	0.00218	CcSEcCtD
Enzalutamide—Pruritus—Gemcitabine—urinary bladder cancer	0.000297	0.00218	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—urinary bladder cancer	0.000296	0.00217	CcSEcCtD
Enzalutamide—Sinusitis—Epirubicin—urinary bladder cancer	0.000296	0.00217	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—urinary bladder cancer	0.000293	0.00215	CcSEcCtD
Enzalutamide—Pruritus—Fluorouracil—urinary bladder cancer	0.000292	0.00214	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000292	0.00214	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—urinary bladder cancer	0.000292	0.00214	CcSEcCtD
Enzalutamide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000287	0.00211	CcSEcCtD
Enzalutamide—Rhinitis—Epirubicin—urinary bladder cancer	0.000284	0.00208	CcSEcCtD
Enzalutamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000283	0.00207	CcSEcCtD
Enzalutamide—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000282	0.00207	CcSEcCtD
Enzalutamide—Asthenia—Cisplatin—urinary bladder cancer	0.000281	0.00206	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000281	0.00206	CcSEcCtD
Enzalutamide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00028	0.00205	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000279	0.00204	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—urinary bladder cancer	0.000278	0.00204	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000278	0.00204	CcSEcCtD
Enzalutamide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000277	0.00203	CcSEcCtD
Enzalutamide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000275	0.00202	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—urinary bladder cancer	0.000274	0.00201	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000274	0.00201	CcSEcCtD
Enzalutamide—Dizziness—Fluorouracil—urinary bladder cancer	0.000273	0.002	CcSEcCtD
Enzalutamide—ABCB1—lymph node—urinary bladder cancer	0.000272	0.00345	CbGeAlD
Enzalutamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000268	0.00196	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—urinary bladder cancer	0.000265	0.00194	CcSEcCtD
Enzalutamide—Headache—Gemcitabine—urinary bladder cancer	0.000263	0.00193	CcSEcCtD
Enzalutamide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000263	0.00193	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000261	0.00191	CcSEcCtD
Enzalutamide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00026	0.00191	CcSEcCtD
Enzalutamide—Headache—Fluorouracil—urinary bladder cancer	0.000259	0.0019	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000259	0.0019	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000258	0.00189	CcSEcCtD
Enzalutamide—Asthenia—Etoposide—urinary bladder cancer	0.000257	0.00189	CcSEcCtD
Enzalutamide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000257	0.00189	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—urinary bladder cancer	0.000257	0.00188	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000257	0.00188	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—urinary bladder cancer	0.000255	0.00187	CcSEcCtD
Enzalutamide—Pruritus—Etoposide—urinary bladder cancer	0.000254	0.00186	CcSEcCtD
Enzalutamide—Mental disorder—Epirubicin—urinary bladder cancer	0.000248	0.00182	CcSEcCtD
Enzalutamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000245	0.0018	CcSEcCtD
Enzalutamide—Back pain—Epirubicin—urinary bladder cancer	0.000238	0.00175	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—urinary bladder cancer	0.000238	0.00174	CcSEcCtD
Enzalutamide—Dizziness—Etoposide—urinary bladder cancer	0.000237	0.00174	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—urinary bladder cancer	0.000237	0.00173	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—urinary bladder cancer	0.000236	0.00173	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000229	0.00168	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—urinary bladder cancer	0.000228	0.00167	CcSEcCtD
Enzalutamide—Headache—Etoposide—urinary bladder cancer	0.000225	0.00165	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—urinary bladder cancer	0.000224	0.00164	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000223	0.00163	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—urinary bladder cancer	0.000221	0.00162	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—urinary bladder cancer	0.000221	0.00162	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—urinary bladder cancer	0.000221	0.00162	CcSEcCtD
Enzalutamide—Convulsion—Epirubicin—urinary bladder cancer	0.000213	0.00157	CcSEcCtD
Enzalutamide—Infection—Methotrexate—urinary bladder cancer	0.000213	0.00157	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—urinary bladder cancer	0.000213	0.00156	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000211	0.00155	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00021	0.00154	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—urinary bladder cancer	0.00021	0.00154	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—urinary bladder cancer	0.000209	0.00153	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—urinary bladder cancer	0.000209	0.00153	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000208	0.00153	CcSEcCtD
Enzalutamide—Vertigo—Doxorubicin—urinary bladder cancer	0.000205	0.0015	CcSEcCtD
Enzalutamide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000204	0.0015	CcSEcCtD
Enzalutamide—Infection—Epirubicin—urinary bladder cancer	0.0002	0.00147	CcSEcCtD
Enzalutamide—Convulsion—Doxorubicin—urinary bladder cancer	0.000198	0.00145	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000197	0.00145	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000197	0.00144	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—urinary bladder cancer	0.000197	0.00144	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000196	0.00144	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—urinary bladder cancer	0.000195	0.00143	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—urinary bladder cancer	0.000194	0.00143	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000194	0.00142	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—urinary bladder cancer	0.000193	0.00142	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000193	0.00141	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000193	0.00141	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000186	0.00136	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—urinary bladder cancer	0.000185	0.00136	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—urinary bladder cancer	0.000185	0.00136	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000183	0.00134	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000182	0.00134	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000182	0.00134	CcSEcCtD
Enzalutamide—Insomnia—Epirubicin—urinary bladder cancer	0.000182	0.00133	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000181	0.00133	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000181	0.00132	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000174	0.00127	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—urinary bladder cancer	0.000173	0.00127	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00017	0.00124	CcSEcCtD
Enzalutamide—Insomnia—Doxorubicin—urinary bladder cancer	0.000168	0.00123	CcSEcCtD
Enzalutamide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000167	0.00123	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000161	0.00118	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—urinary bladder cancer	0.00016	0.00118	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—urinary bladder cancer	0.000154	0.00113	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—urinary bladder cancer	0.000152	0.00111	CcSEcCtD
Enzalutamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000147	0.00108	CcSEcCtD
Enzalutamide—Asthenia—Epirubicin—urinary bladder cancer	0.000144	0.00106	CcSEcCtD
Enzalutamide—Pruritus—Epirubicin—urinary bladder cancer	0.000142	0.00104	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—urinary bladder cancer	0.000142	0.00104	CcSEcCtD
Enzalutamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000138	0.00101	CcSEcCtD
Enzalutamide—Headache—Methotrexate—urinary bladder cancer	0.000135	0.000987	CcSEcCtD
Enzalutamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000133	0.000979	CcSEcCtD
Enzalutamide—Dizziness—Epirubicin—urinary bladder cancer	0.000133	0.000975	CcSEcCtD
Enzalutamide—Pruritus—Doxorubicin—urinary bladder cancer	0.000132	0.000965	CcSEcCtD
Enzalutamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000127	0.000934	CcSEcCtD
Enzalutamide—Headache—Epirubicin—urinary bladder cancer	0.000126	0.000924	CcSEcCtD
Enzalutamide—Dizziness—Doxorubicin—urinary bladder cancer	0.000123	0.000902	CcSEcCtD
Enzalutamide—Headache—Doxorubicin—urinary bladder cancer	0.000117	0.000855	CcSEcCtD
Enzalutamide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	3.87e-05	0.000349	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.85e-05	0.000347	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.78e-05	0.000341	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—TYMP—urinary bladder cancer	3.77e-05	0.00034	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.76e-05	0.000339	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—TYMP—urinary bladder cancer	3.68e-05	0.000332	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—ERCC2—urinary bladder cancer	3.68e-05	0.000332	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.65e-05	0.000329	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.57e-05	0.000322	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	3.56e-05	0.000321	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	3.56e-05	0.000321	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.54e-05	0.000319	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.53e-05	0.000318	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.48e-05	0.000313	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NAT2—urinary bladder cancer	3.41e-05	0.000307	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.4e-05	0.000306	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.36e-05	0.000303	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.33e-05	0.0003	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.33e-05	0.0003	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	3.32e-05	0.0003	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.29e-05	0.000297	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.28e-05	0.000296	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.28e-05	0.000295	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.25e-05	0.000293	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.2e-05	0.000288	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—TYMP—urinary bladder cancer	3.19e-05	0.000288	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.18e-05	0.000287	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—TYMP—urinary bladder cancer	3.17e-05	0.000286	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.13e-05	0.000282	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.09e-05	0.000279	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—ESR1—urinary bladder cancer	3.08e-05	0.000277	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.06e-05	0.000276	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.05e-05	0.000275	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.04e-05	0.000274	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.98e-05	0.000269	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—RRM2—urinary bladder cancer	2.94e-05	0.000265	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PLAU—urinary bladder cancer	2.92e-05	0.000263	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.88e-05	0.00026	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.87e-05	0.000259	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NAT2—urinary bladder cancer	2.87e-05	0.000259	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.85e-05	0.000257	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.85e-05	0.000257	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.83e-05	0.000255	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.83e-05	0.000255	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PPARG—urinary bladder cancer	2.81e-05	0.000253	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.78e-05	0.000251	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.73e-05	0.000247	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.73e-05	0.000246	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	2.72e-05	0.000246	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ENO2—urinary bladder cancer	2.72e-05	0.000246	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—CREBBP—urinary bladder cancer	2.7e-05	0.000243	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.67e-05	0.00024	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.66e-05	0.00024	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.66e-05	0.00024	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	2.64e-05	0.000238	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.62e-05	0.000236	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.6e-05	0.000235	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.6e-05	0.000234	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.58e-05	0.000233	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.58e-05	0.000233	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.57e-05	0.000232	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.54e-05	0.000229	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.52e-05	0.000227	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.51e-05	0.000227	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.49e-05	0.000225	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.49e-05	0.000224	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—RRM2—urinary bladder cancer	2.48e-05	0.000223	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.4e-05	0.000217	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IGF1—urinary bladder cancer	2.38e-05	0.000214	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.37e-05	0.000213	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.35e-05	0.000212	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.33e-05	0.00021	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.31e-05	0.000208	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.31e-05	0.000208	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—HPGDS—urinary bladder cancer	2.29e-05	0.000207	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ENO2—urinary bladder cancer	2.29e-05	0.000207	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.29e-05	0.000207	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.28e-05	0.000206	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.24e-05	0.000202	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.24e-05	0.000202	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTT1—urinary bladder cancer	2.22e-05	0.0002	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.22e-05	0.0002	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.2e-05	0.000199	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.2e-05	0.000198	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.2e-05	0.000198	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.19e-05	0.000197	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—RHOA—urinary bladder cancer	2.18e-05	0.000196	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.17e-05	0.000196	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.15e-05	0.000193	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.14e-05	0.000193	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.08e-05	0.000188	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.06e-05	0.000186	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.06e-05	0.000186	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.05e-05	0.000184	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.04e-05	0.000184	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.03e-05	0.000183	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.01e-05	0.000181	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.01e-05	0.000181	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2e-05	0.00018	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.97e-05	0.000177	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.95e-05	0.000176	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.89e-05	0.000171	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.89e-05	0.000171	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.88e-05	0.000169	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.88e-05	0.000169	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.87e-05	0.000168	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.86e-05	0.000168	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NQO1—urinary bladder cancer	1.85e-05	0.000167	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.84e-05	0.000166	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.83e-05	0.000165	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL2—urinary bladder cancer	1.83e-05	0.000165	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.82e-05	0.000164	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.82e-05	0.000164	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.8e-05	0.000163	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.79e-05	0.000162	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.79e-05	0.000162	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.79e-05	0.000161	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.71e-05	0.000154	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.7e-05	0.000153	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.68e-05	0.000152	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.68e-05	0.000152	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.66e-05	0.00015	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.66e-05	0.00015	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.64e-05	0.000148	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.64e-05	0.000148	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—EP300—urinary bladder cancer	1.64e-05	0.000148	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.62e-05	0.000146	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.61e-05	0.000145	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.61e-05	0.000145	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MYC—urinary bladder cancer	1.6e-05	0.000144	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SRC—urinary bladder cancer	1.59e-05	0.000144	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.58e-05	0.000143	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.57e-05	0.000142	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.57e-05	0.000142	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.56e-05	0.000141	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.55e-05	0.00014	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.55e-05	0.00014	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000139	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTP1—urinary bladder cancer	1.54e-05	0.000139	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.53e-05	0.000138	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.51e-05	0.000136	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.5e-05	0.000135	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.49e-05	0.000134	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.49e-05	0.000134	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.47e-05	0.000132	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.45e-05	0.000131	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.44e-05	0.00013	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—TYMS—urinary bladder cancer	1.43e-05	0.000129	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	0.000128	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	0.000128	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	0.000128	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	0.000128	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.000127	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000125	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.000123	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.000122	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.35e-05	0.000122	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.34e-05	0.000121	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.34e-05	0.000121	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.34e-05	0.00012	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ERCC2—urinary bladder cancer	1.33e-05	0.00012	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—KRAS—urinary bladder cancer	1.32e-05	0.000119	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.29e-05	0.000116	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.28e-05	0.000115	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	0.000115	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000115	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000115	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.26e-05	0.000114	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.26e-05	0.000114	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.26e-05	0.000113	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—MTHFR—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.22e-05	0.00011	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.22e-05	0.00011	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.21e-05	0.000109	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.2e-05	0.000108	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.2e-05	0.000108	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.19e-05	0.000107	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.18e-05	0.000107	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000106	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000106	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—urinary bladder cancer	1.17e-05	0.000106	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	0.000105	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	0.000105	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	0.000105	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.16e-05	0.000104	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—HRAS—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.11e-05	0.0001	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	9.91e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	9.89e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.09e-05	9.83e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	9.32e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	9.24e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.02e-05	9.2e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPARG—urinary bladder cancer	1.02e-05	9.15e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.98e-06	8.99e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.81e-06	8.84e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CREBBP—urinary bladder cancer	9.75e-06	8.79e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	9.49e-06	8.55e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	9.27e-06	8.36e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.11e-06	8.22e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.89e-06	8.02e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	8.75e-06	7.89e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.54e-06	7.7e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	8.38e-06	7.56e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.32e-06	7.5e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.31e-06	7.49e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTEN—urinary bladder cancer	8.27e-06	7.46e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.09e-06	7.29e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.05e-06	7.26e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	8.03e-06	7.24e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTGS2—urinary bladder cancer	7.98e-06	7.2e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.98e-06	7.2e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—EP300—urinary bladder cancer	7.89e-06	7.11e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.73e-06	6.97e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—EP300—urinary bladder cancer	7.71e-06	6.95e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.65e-06	6.89e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.65e-06	6.89e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.32e-06	6.6e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.19e-06	6.48e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.17e-06	6.46e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	7e-06	6.31e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	7e-06	6.31e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTEN—urinary bladder cancer	6.96e-06	6.28e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.76e-06	6.09e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.68e-06	6.02e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—EP300—urinary bladder cancer	6.64e-06	5.99e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.59e-06	5.94e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.54e-06	5.89e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.25e-06	5.64e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.1e-06	5.5e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.96e-06	5.38e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—EP300—urinary bladder cancer	5.82e-06	5.25e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.75e-06	5.18e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.7e-06	5.14e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.48e-06	4.94e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.48e-06	4.94e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.44e-06	4.9e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.26e-06	4.75e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.31e-06	3.89e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.76e-06	3.39e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.58e-06	3.23e-05	CbGpPWpGaD
